PharmaCyte Biotech, Inc. entered into a Consent and Warrant Exchange Agreement with Q/C Technologies, Inc. on November 15, 2026. Under the agreement, the Company exchanged 851,304 Series G Long-Term Warrants to purchase shares of Q/C Common Stock for an aggregate of 4,982,272 shares of Q/C Common Stock. The number of shares issued was calculated based on the Black-Scholes value of the exchanged warrants divided by $0.3101 per share, which was the closing price of Q/C Common Stock on the last trading day prior to the agreement's execution. The Company paid no additional consideration for this exchange.

In addition to the warrant exchange, PharmaCyte, as the majority holder of Q/C’s Series H Convertible Preferred Stock, consented to an amendment to the Certificate of Designations for that preferred stock. This amendment extends the maturity date of the Series H Preferred Stock from March 2, 2027, to September 2, 2027. The Company did not pay consideration for this amendment.

The Exchange Shares have not been registered under the Securities Act of 1933. Pursuant to the agreement, Q/C is required to file a resale registration statement with the Securities and Exchange Commission to register the shares for resale within 30 days of receiving a demand from PharmaCyte, beginning 90 days after the warrant exchange.